Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Possibilities of modern antiplatelet and antithrombotic therapy at percutaneous coronary interventions in patients with coronary artery disease are surveyed. Data of multicenter randomized clinical trials and meta-analyses are discussed. Possibilities of various drugs at percutaneous coronary interventions are reported from position of the international clinical guidelines.

About the Author

V. A. Sulimov
Moscow Medical Academy named after I.M. Setchenov
Russian Federation
Chair of Faculty Therapy N1, Clinic of Faculty Therapy and Interventional Cardiology


1. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation 1995;92:657–61

2. Furie B., Furie B.C. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800–6.

3. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1 and 2). N Engl J Med 1992;326:242–50;310-8.

4. Savage M.P., Goldberg S., Bove A. A., et al. Effect of thromboxane A2 blockade jn clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation 1995; 92:3194-200.

5. The Anti-Thrombotic Trialist’s Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMed J 2002;324:71-86.

6. Guidelines for Percutaneous Coronary Interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-47.

7. King S.B. III, Smith S.C. Jr, Hirshfeld J.W. Jr et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guidline Update for Percutaneous Coronary Intervention: a report of the American College og Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guidline Update for Percutaneouse Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008;117:261–95.

8. Herbert J.M., Savi P. P2Y12, a new platelet ADP receptor, target of Clopidogrel. Semin Vasc Med 2003;3(2):113-22.

9. Cadroy Y., Bossavy J.P., Thalamas C., et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000;101:2823–8.

10. Schomig A., Neumann F. J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. (ISAR). N Engl J Med 1996;334:1084-9.

11. Leon M.B., Baim D.S., Popma J.J. et al. A clinical trial comparing tree anti-thrombotic-drugregiments after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators (STARS). N Engl J Med 1998;339:1665-71.

12. Bertrand M.E., Legrand V., Boland J. et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998;98(16):1597-603.

13. Urban P., Macaya C., Rupprecht H.J. et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998;98(20):2126-32.

14. Bennett C.L., Weinberg P.D., Rozenberg-Ben-Dror K. et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998;128(7):541-4.

15. Capra R., Marciano N., Fieni F. et al. Cerebral hemorrhage and thrombotic thrombocytopenic purpura during ticlopidine treatment: case report. Acta Neurol Belg 1992;92:83-7.

16. Kovacs M.J., Soong P.Y., Chin-Hee I.H. Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Pharmacother 1993;27:1060-1.

17. Kupfer Y., Tessler S. Ticlopidine and thrombotic thrombocytopenic purpura [Letter]. N Engl J Med 1997;337:1245.

18. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–39.

19. Bhatt D. L., Bertrand M. E., Berger P. B. et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39:9–14.

20. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007; 28:1598–660.

21. Mehta S.R., Yusuf S., Peters R.J., for the CURE investigators: Effects of pretreatment with clopidogrel and aspirin following by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527–33.

22. Steinhubl S. R., Berger P. B., Mann J. T. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 2002;288:2411–20.

23. Savcic M., Hauert J., Bachmann F. et al. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 1999;25(suppl 2):15–29.

24. Kastrati A., Mehilli J., Schuhlen H. et al. Intracoronary Stenting and Antiyhrombotic Regimen – Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350:232-8.

25. Patti G., Colonna G., Pasceri V. et al. Randimized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary interventions: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study. Circulation 2005; 111:2099–106.

26. Montalescot G., Sideris G., Meuleman C. et al., ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2006;48:931–8.

27. Von Beckerath N., Taubert D., Pogatsa-Murray G. et al. Absorption, metabolization, and antiplatelet effects of 300- ,600- , and 900-mg loading doses of clopidogrel. Results of the ISARCHOICE trial. Circulation 2005;112:2946-50.

28. Sabatine M.S., Cannon C.P., Gibson C.M. et al for the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179–89.

29. COMMIT (clopidogrel and metoprolol in myocardial infarction trial) Collaborative Group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21.

30. Sabatine M.S., Cannon C.P., Gibson C.M. et al. Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY) – Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics. The PCI-CLARITY study. JAMA 2005;294:1224-32.

31. Wiviott S.D., Trenk D., Frelinger A.L. et al. PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial. Circulation 2007;116:2923–32.

32. Wiviott S.D., Antman E.M., Gibson C.M. et al. JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary interventions. Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO) – TIMI 26 trial. Circulation 2005;111:3366–73.

33. Wiviott S.D., Braunwald E., McCabe C. Y. et al., the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15.

34. Greenbaum A.B., Grines C.L., Bittl J.A. et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006;151:689.e1-689.e10.

35. Husted S., Emanuelsson H., Heptinstall S. et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin (DISPERSE trial). Eur Heart J 2006;27:1038-47.

36. Cannon C. P., Husted S., Harrington R.A. et al., for the DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844–51.

37. Claeys M.J., Van Der Planken M.G., Michiels J.J. et al. Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention. Blood Coagul Fibrinolysis 2002;13:283–8.

38. Kong D.F., Hasselblat V., Harrington R.A. et al. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol 2003;92:651–655.

39. Montalescot G., White H.D., Gallo R. et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006-17.

40. Kereiakes D.L., Montalescot G., Antman E.M. et al. Low-molecular-weight heparin therapy for non-ST-Elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. Am Heart J 2002;144:615–24.

41. Ferguson J.J., Califf R.M., Antman E.M. et al. Enoxaparin vs unfractionated heparin in high–risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45–54.

42. Mehta S.R., Granger C.B., Eikelboom J.W. et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Results from the OASIS-5 trial. J Am Coll Cardiol 2007;50:1742-51.

43. Yusuf S., Mehta S.R., Chrolavicius S. et al., OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295:1519–30.

44. Lincoff A.M., Bittl J.A., Harrington R.A. et al.; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-63.

45. Stone G.W., White H.D., Ohman E.M. et al.; Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007;369:907-19.

46. Stone G.W., Witzenbichler B., Guagliumi G. et al.; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30.

For citation:

Sulimov V.A. ANTITHROMBOTIC THERAPY AT PERCUTANEOUS CORONARY INTERVENTIONS. Rational Pharmacotherapy in Cardiology. 2008;4(3):91-100. (In Russ.)

Views: 298

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)